Skip to content

A Clinical Study for Safety And Efficacy of Microbubble-United Diagnostic Ultrasound Sensitize the Chemotherapy of Medium And Severe Acute Leukemia

Microbubble-United Diagnostic Ultrasound Sensitize Medium And Severe Acute Leukemia Chemotherapy: A Clinical Study for Safety And Efficacy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023127
Enrollment
Unknown
Registered
2019-05-12
Start date
2019-05-20
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Interventions

Group 1:microbubble injection
Group 2:ultrasound exposure in spleen

Sponsors

Chongqing Xinqiao Hospital (The Second Hospital Of The Army Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. First-diagnosed acute leukemia , risk stratification is medium or/and high and never be sonicated before. 2. Diagnosed with no response or relapse acute leukemia and never be sonicated before. 3. Presumed life-time is longer than 2 months; 4. Performance status is 0 to 2; 5. Aged 18 to 60 years male and female; 6. Normal Heart and lung function; 7. Sigh informed consent.

Exclusion criteria

Exclusion criteria: 1. with other severe disease such as newly myocardial infarction, congestive heart failure, severe lung disease; 2. Allergic to ultrasound contrast agent; 3. with active or uncontrolled bleeding, such as active peptic ulcer; 4. With history of Severe infection; 5. With central nervous system disease or epidural solid tumor or other hematological tumor, malignancy tumor; 6. Pregnant or lactating; 7. Expectation life time less than 2 moth; 8. Undergone splenectomy; 9. participate other clinical trail within 4 weeks; 10. dissent or nonobservant of the treatment; 11. With history of radiotherapy or surgery or hormonotherapy within two weeks.

Design outcomes

Primary

MeasureTime frame
bone marrow myeloblast;antigen presentation;blood routine;

Secondary

MeasureTime frame
Left ventricle ejection fraction;Lactate Dehydrogenase;renal function test;liver function;

Countries

China

Contacts

Public ContactZheng Liu

Chongqing Xinqiao Hospital (The Second Hospital Of The Army Medical University)

liuzhengs@hotmail.com+86 18602395775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026